| CLSI-derived hematology and biochemistry reference intervals for healthy adults in eastern and southern Africa E Karita, N Ketter, MA Price, K Kayitenkore, P Kaleebu, A Nanvubya, ... PloS one 4 (2), e4401, 2009 | 205 | 2009 |
| Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and … BS Peters, W Jaoko, E Vardas, G Panayotakopoulos, P Fast, C Schmidt, ... Vaccine 25 (11), 2120-2127, 2007 | 125 | 2007 |
| Safety and immunogenicity study of Multiclade HIV-1 adenoviral vector vaccine alone or as boost following a multiclade HIV-1 DNA vaccine in Africa W Jaoko, E Karita, K Kayitenkore, G Omosa-Manyonyi, S Allen, S Than, ... PloS one 5 (9), e12873, 2010 | 114 | 2010 |
| Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa W Jaoko, FN Nakwagala, O Anzala, GO Manyonyi, J Birungi, A Nanvubya, ... Vaccine 26 (22), 2788-2795, 2008 | 105 | 2008 |
| Systematic review of the performance and clinical utility of point of care HIV-1 RNA testing for diagnosis and care CA Agutu, CJ Ngetsa, MA Price, TF Rinke de Wit, G Omosa-Manyonyi, ... PloS one 14 (6), e0218369, 2019 | 51 | 2019 |
| First-in-human evaluation of the safety and immunogenicity of an intranasally administered replication-competent Sendai virus–vectored hiv type 1 gag vaccine: Induction of … J Nyombayire, O Anzala, B Gazzard, E Karita, P Bergin, P Hayes, ... The Journal of Infectious Diseases 215 (1), 95, 2017 | 44 | 2017 |
| A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of an Adjuvanted HIV-1 Gag-Pol-Nef Fusion Protein and Adenovirus 35 Gag-RT-Int-Nef … G Omosa-Manyonyi, J Mpendo, E Ruzagira, W Kilembe, E Chomba, ... PloS one 10 (5), e0125954-e0125954, 2015 | 40 | 2015 |
| Knowledge of HIV transmission and associated factors among HIV-positive and HIV-negative patients in rural Kenya SY Hong, D Thompson, C Wanke, G Omosa, MR Jordan, AM Tang, ... Journal of AIDS & clinical research 3 (7), 2012 | 38 | 2012 |
| Prevalence and factors associated with contraceptive use among Kenyan women aged 15–49 years LL Lunani, A Abaasa, G Omosa-Manyonyi AIDS and Behavior 22, 125-130, 2018 | 31 | 2018 |
| Reasons for ineligibility in phase 1 and 2A HIV vaccine clinical trials at Kenya AIDS vaccine initiative (KAVI), Kenya GS Omosa-Manyonyi, W Jaoko, O Anzala, H Ogutu, S Wakasiaka, ... PloS one 6 (1), e14580, 2011 | 29 | 2011 |
| Hepatitis B virus incidence and risk factors among human immunodeficiency virus-1 negative men who have sex with men in Kenya E Wahome, C Ngetsa, J Mwambi, HC Gelderblom, GO Manyonyi, ... Open forum infectious diseases 4 (1), ofw253, 2017 | 28 | 2017 |
| Acceptance of treatment of sexually transmitted infections for stable sexual partners by female sex workers in Kampala, Uganda Y Mayanja, AD Mukose, S Nakubulwa, G Omosa-Manyonyi, A Kamali, ... PLoS One 11 (5), e0155383, 2016 | 16 | 2016 |
| Reported willingness to participate in a hypothetical HIV vaccine trial and its translation to actual participation among healthy adults—Experience from Kenya DK Nyasani, GN Mutua, RM Sajabi, JW Ng’ang’a, JN Gachie, AM Maina, ... PloS one 13 (11), e0206656, 2018 | 15 | 2018 |
| Using a multimethod approach to develop implementation strategies for a cervical self-sampling program in Kenya I Podolak, C Kisia, G Omosa-Manyonyi, J Cosby BMC health services research 17, 1-15, 2017 | 15 | 2017 |
| Assessment of Anti–HIV-1 Antibodies in Oral and Nasal Compartments of Volunteers From 3 Different Populations PJ Bergin, R Langat, G Omosa-Manyonyi, B Farah, G Ouattara, H Park, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 73 (2), 130-137, 2016 | 12 | 2016 |
| Long-term follow-up of study participants from prophylactic HIV vaccine clinical trials in Africa C Schmidt, W Jaoko, G Omosa-Manyonyi, P Kaleebu, J Mpendo, ... Human Vaccines & Immunotherapeutics 10 (3), 714-723, 2014 | 11 | 2014 |
| Willingness to participate in future HIV vaccine trials among men who have sex with men and female sex workers living in Nairobi, Kenya EM Mutisya, G Mutua, D Nyasani, H Nduta, RW Kabuti, V Muturi-Kioi, ... PLoS One 15 (8), e0238028, 2020 | 10 | 2020 |
| Acceptability and feasibility of repeated mucosal specimen collection in clinical trial participants in Kenya G Omosa-Manyonyi, H Park, G Mutua, B Farah, PJ Bergin, D Laufer, ... PLoS One 9 (10), e110228, 2014 | 10 | 2014 |
| Safety and immunogenicity of DNA and MVA HIVA vaccines in phase I HIV-1 vaccine trials in Nairobi, Kenya W Jaoko, G Omosa, K Bhatt, L Matu, H Ogutu AIDS Vaccine 4, 2004 | 7 | 2004 |
| Performance of International AIDS Vaccine Initiative African clinical research laboratories in standardised ELISpot and peripheral blood mononuclear cell processing in support … RK Langat, B Farah, J Indangasi, S Ogola, G Omosa-Manyonyi, O Anzala, ... African Journal of Laboratory Medicine 10 (1), 1-13, 2021 | 5 | 2021 |
